[en] Exposure-response modeling and simulation is especially useful in oncology as it permits to predict and design un-experimented clinical trials as well as dose selection. Dendritic cells (DC) are the most effective immune cells in the regulation of immune system. To activate immune system, DCs may be matured by many factors like bacterial CpG-DNA, Lipopolysaccharaide (LPS) and other microbial products. In this paper, a model based on artificial neural network (ANN) is presented for analyzing the dynamics of antitumor vaccines using empirical data obtained from the experimentations of different groups of mice treated with DCs matured by bacterial CpG-DNA, LPS and whole lysate of a Gram-positive bacteria Listeria monocytogenes. Also, tumor lysate was added to DCs followed by addition of maturation factors. Simulations show that the proposed model can interpret the important features of empirical data. Owing to the nonlinearity properties, the proposed ANN model has been able not only to describe the contradictory empirical results, but also to predict new vaccination patterns for controlling the tumor growth. For example, the proposed model predicts an exponentially increasing pattern of CpG-matured DC to be effective in suppressing the tumor growth.
Disciplines :
Engineering, computing & technology: Multidisciplinary, general & others
Author, co-author :
Mehrian, Mohammad ; Université de Liège - ULiège > Département d'aérospatiale et mécanique > Génie biomécanique
Asemani, Davud
Arabameri, Abazar
Pourgholaminejad, Arash
Hadjati, Jamshid
Language :
English
Title :
Modeling of tumor growth in dendritic cell-based immunotherapy using artificial neural networks.
Publication date :
2014
Journal title :
Computational Biology and Chemistry
ISSN :
1476-9271
eISSN :
1476-928X
Publisher :
Elsevier, United Kingdom
Volume :
48
Pages :
21-8
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2013 Elsevier Ltd. All rights reserved.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
M. Bodnar, and U. Forys Three types of simple DDE's describing tumor growth Journal of Biological Systems 15 04 2007 453 471
P. Bousso T-cell activation by dendritic cells in the lymph node: lessons from the movies Nature Reviews Immunology 8 9 2008 675 684
R. Bruno Population pharmacokinetic and pharmacokinetic-pharmacodynamic relationships for docetaxel Investigational New Drugs 19 2001 163L 69
L.E.B. Cabrales Mathematical modeling of tumor growth in mice following low-level direct electric current Mathematics and Computers in Simulation 78 1 2008 112 120
J.A. Cintolo Dendritic cell-based vaccines: barriers and opportunities Future Oncology 8 10 2012 1273 1299
L. Claret Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics Journal of Clinical Oncology 27 25 2009 4103 4108
S. Cornet CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope Vaccine 24 11 2006 1880 1888
M. Danhof Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research Trends in Pharmacological Sciences 29 4 2008 186 191
R. Eftimie, J.L. Bramson, and D.J. Earn Interactions between the immune system and cancer: a brief review of non-spatial mathematical models Bulletin of Mathematical Biology 73 1 2011 2 32
Fujimoto-Ouchi Antitumor activity of combinations of anti- HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5-dFUrd in human breast cancer models Cancer Chemotherapy and Pharmacology 49 2002 211 216
F. Granucci Early events in dendritic cell maturation induced by LPS Microbes and Infection 1 13 1999 1079 1084
L.A. Hammond Enhanced antitumour activity of 6-xenograft hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma model European Journal of Cancer 36 2000 2430 2436
S. Jönsson Contribution of modeling and simulation studies in the regulatory review: a European regulatory perspective Clinical Trial Simulations 2011 Springer New York 15 36
G. Koch Modeling of tumor growth and anticancer effects of combination therapy Journal of Pharmacokinetics and Pharmacodynamics 36 2 2009 179 197
R.L. Lalonde Model-based drug development Clinical Pharmacology & Therapeutics 82 1 2007 21 32
A. Lanzavecchia, and F. Sallusto Regulation of T cell immunity by dendritic cells Cell 106 3 2001 263 266
P.M. LoRusso Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer Journal of Clinical Oncology 26 18 2008 3051 3056
M.A. Morse Dendritic cell maturation in active immunotherapy strategies Expert Opinion on Biological Therapy 2 1 2002 35 43
J.D. Olden, and D.A. Jackson Illuminating the black box: a randomization approach for understanding variable contributions in artificial neural networks Ecological Modelling 154 1 2002 135 150
R. Pili Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis Cancer Research 61 2001 1477 1485
T. Roose Mathematical models of avascular tumor growth Siam Review 49 2 2007 179 208
M. Rowland Physiologically-based pharmacokinetics in drug development and regulatory science Annual Review of Pharmacology and Toxicology 51 2011 45 73
P. Sharma Novel cancer immunotherapy agents with survival benefit: recent successes and next steps Nature Reviews Cancer 11 11 2011 805 812
J.A. Sparano Weekly paclitaxel in the adjuvant treatment of breast cancer New England Journal of Medicine 358 16 2008 1663 1671
J.L. Tanyi, and C.S. Chu Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review Future Oncology 8 10 2012 1273 1299
M. Tod Facilitation of drug evaluation in children by population methods and modelling Clinical Pharmacokinetics 47 4 2008 231 243
P.H. Van der Graaf, and N. Benson Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development Pharmaceutical Research 28 7 2011 1460 1464
C.H. Van Kesteren Pharmacokinetic-pharmacodynamic guided trial design in oncology Investigational New Drugs 21 2 2003 225 241
C. Van Kesteren Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study Clinical Cancer Research 6 12 2000 4725 4732
H. Xie Time series prediction based on NARX neural networks: An advanced approach Machine Learning and Cybernetics, 2009 International Conference on IEEE vol. 3 2009 1275 1279
T.A. Yap Envisioning the future of early anticancer drug development Nature Reviews Cancer 10 7 2010 514 523
L. Zhang Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis Cancer Research 62 7 2002 2034 2042
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.